Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to Cisplatin
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
This study was to investigate the role of Fas in the developmentof Cisplatin-resistant ovarian cancer. On the cellularlevel, Fas expression was significantly reduced in Cisplatinresistant A2780 (A2780/CP) cells compared with A2780 cells. Fas silence with siRNA would promote tumor cell linesproliferation, facilitate tumor cell cycle transition of G1/S,prevent cell apoptosis, and promote cell migration. Expressionof drug resistance gene was negatively correlated to Fas. Innude mice metastasis model of human ovarian carcinoma bysubcutaneous transplantation, after Ad-Fas injected intratumorly,we found that upregulation of Fas could inhibit transplantationtumor tissue growth and reduce the expression of drugresistance gene. Our results indicated that upregulation of Fasin epithelial ovarian cancer reversed the development ofresistance to Cisplatin. In conclusion, our findings suggestedthat Fas might act as a promising therapeutic target for improvementof the sensibility to Cisplatin in ovarian cancer.
Abstract
This study was to investigate the role of Fas in the developmentof Cisplatin-resistant ovarian cancer. On the cellularlevel, Fas expression was significantly reduced in Cisplatinresistant A2780 (A2780/CP) cells compared with A2780 cells. Fas silence with siRNA would promote tumor cell linesproliferation, facilitate tumor cell cycle transition of G1/S,prevent cell apoptosis, and promote cell migration. Expressionof drug resistance gene was negatively correlated to Fas. Innude mice metastasis model of human ovarian carcinoma bysubcutaneous transplantation, after Ad-Fas injected intratumorly,we found that upregulation of Fas could inhibit transplantationtumor tissue growth and reduce the expression of drugresistance gene. Our results indicated that upregulation of Fasin epithelial ovarian cancer reversed the development ofresistance to Cisplatin. In conclusion, our findings suggestedthat Fas might act as a promising therapeutic target for improvementof the sensibility to Cisplatin in ovarian cancer.
참고문헌 (24)
- Jemal A, "Cancer statistics", CA Cancer J Clin, 57, pp.43~66 (2007)
- Broxterman HJ, "Understanding the causes of multidrug resistance in cancer:a comparison of doxorubicin and sunitinib", Drug Resist Updat, 12, pp.114~126 (2009)
- Song IS, "Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in Cisplatin-sensitive and Cisplatin-resistant cells", Mol Cancer Ther, 3, pp.1543~1549 (2004)
- Stefansson OA, "BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer", Epigenetics, 7, pp.1225~1229 (2012)
- Lin C, "NOXA-induced alterations in the Bax", Smac axis enhance sensitivity of ovarian cancer cells to Cisplatin, 2012, pp.7, e36722~
- Johnson SW, "Increased platinum-DNA damage tolerance is associated with Cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines", Cancer Res, 57, pp.850~856 (1997)
- Siddik ZH, "Cisplatin : mode of cytotoxic action and molecular basis of resistance", Oncogene, 22, pp.7265~7279 (2003)
- Locksley RM, "The TNF and TNF receptor superfamilies: integrating mammalian biology", Cell, 104, pp.487~501 (2001)
- Desbarats J, "Fas engagement induces neurite growth through ERK activation and p35upregulation", Nat Cell Biol, 5, pp.118~125 (2003)
- Golubovskaya VM, "Focal adhesion kinase and cancer", Histol Histopathol, 24, pp.503~510 (2009)
- Kuhajda FP, "Fatty acid synthase and cancer: new application of an old pathway", Cancer Res, 66, pp.5977~5980 (2006)
- Halder J, "Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma", Cancer Res, 67, pp.10976~10983 (2007)
- Zhou W, "Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells", Cancer Res, 67, pp.2964~2971 (2007)
- Wu W, "Up-regulation of Fas reverses Cisplatin resistance of human small cell lung cancer cells", J Exp Clin Cancer Res, 29, pp.49~ (2010)
- Liu WH, "Fas", FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells:ADAM10 down-regulation activates Fas, Int J Biochem Cell Biol, pp.2011, 43[DOI]
- Cai X, "Overcoming Fas-mediated apoptosis accelerates Helicobacter-induced gastric cancer in mice", Cancer Res, 65, pp.10912~10920 (2005)
- "Nature", 2011, 523~526
- Fauvet R, "Expression of pro-apoptotic(p53, p21, bax, bak and fas)and anti-apoptotic(bcl-2 and bcl-x)proteins in serous versus mucinous borderline ovarian tumours", J Surg Oncol, 92, pp.337~343 (2005)
- Zhou W, "Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells", Cancer Res, 67, pp.2964~2971 (2007)
- Yamaguchi H, "Cell migration in tumors", Curr Opin Cell Biol, 17, pp.559~564 (2005)
- Yap TA, "Beyond chemotherapy:targeted therapies in ovarian cancer", Nat Rev Cancer, 9, pp.167~181 (2009)
- Behrens BC, "Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues", Cancer Res, 47, pp.414~418 (1987)
- Caldecott KW, "Construction of human XRCC1 minigenes that fully correct the CHO DNA repair mutant EM9", Nucleic Acids Res, 20, pp.4575~4579 (1992)
- Li P, "SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma", J Transl Med, 11, pp.52~ (2013)